Tectonic Therapeutic (TECX) investor relations material

Executive summary

• Focused on developing biologic medicines targeting GPCRs, with lead candidates TX45 (for pulmonary hypertension) and TX2100 (for hereditary hemorrhagic telangiectasia) in Phase 2 and Phase 1a trials, respectively.

• Completed enrollment in the APEX Phase 2 trial for TX45 for PH-HFpEF; topline results expected early Q1 2027.

• TX2100 Phase 1a trial dosing completed in healthy volunteers; topline results expected by end of Q3 2026.

• Cash and cash equivalents totaled $227.1 million as of June 30, 2026, expected to fund operations into Q1 2029.

Financial highlights

• Net loss of $22.3 million for Q2 2026, up from $20.0 million in Q2 2025; net loss of $47.5 million for the first half of 2026, up from $35.9 million year-over-year.

• Operating expenses rose 8% year-over-year for Q2 and 27% for the first half, driven by increased R&D and G&A costs.

• R&D expenses were $18.0 million and G&A expenses were $6.2 million for Q2 2026, both up year-over-year.

• Cash and cash equivalents decreased from $236.9 million at March 31, 2026, to $227.1 million at June 30, 2026.

• No revenue generated; company remains pre-commercial.

Outlook and guidance

• Cash runway expected to fund operations into Q1 2029, supporting clinical milestones for TX45 and TX2100.

• Anticipates continued increase in R&D and G&A expenses as clinical programs advance.

• Additional capital will be required for future development and commercialization.